Product Name: PAktide KinSub
Product Number: PE-01ADH95
Size: 200 µg      Price:32.00
1 mg      $US64.00
5 mg      140.00
Peptide Name: PAktide KinSub

Product Use: For assaying the phosphotransferase activities of p21-activated kinases PAK1 (UniProt ID Q13153), PAK2 (UniProt ID Q13177), PAK4 (UniProt ID O96013); and PAK6 (UniProt ID Q9NQU5).

Peptide Production Method: Solid-phase peptide synthesis

Peptide Sequence: RRRLSFAEPG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Free carboxyl

Peptide Molecular Mass Calculated: 1187.5 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Peptide Recommended Enzyme: PAK1

Scientific Background: PAK1 is a protein-serine/threonine kinase that is a member of the STE group of protein kinases in the STE20 family, and PAKA subfamily. This kinase is highly expressed and widely distributed in most tested human tissues. PAK1 has been implicated in the regulation of cytoskeletal organization, and cell proliferation and survival, morphology, motility and transformation. Binding of GTP-bound Cdc42 or Rac1 to the autoregulatory region at the N-terminus of PAK1 releases monomers from the autoinhibited dimer, enables phosphorylation at T423 and activation of its phosphotransferase activity. It is also activated by binding to GTP-bound Cdc42, independent of the phosphorylation state of T423. Phosphorylation of S144, S149, and T423 increases PAK1's phosphotransferase activity, whereas phosphorylation of T84 (by OXSR1) and Y212 inhibits its phosphotransferase activity. Phosphorylation of S21 inhibits binding of Nck and PIX. PAK1 may be a therapeutic target in B-Raf wild-type melanoma. Knockdown of PAK1 has been shown to inhibit the proliferation of mutant KRAS colon cancer cells.